- Investing Ideas
- U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
8
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
8 companies
AbbVie
Market Cap: US$398.3b
A research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
ABBV
US$224.95
7D
3.6%
1Y
17.5%
Merck
Market Cap: US$295.4b
Operates as a healthcare company worldwide.
MRK
US$119.09
7D
3.8%
1Y
48.3%
Travere Therapeutics
Market Cap: US$4.5b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$46.74
7D
3.4%
1Y
221.9%
Mesa Laboratories
Market Cap: US$602.4m
Develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally.
MLAB
US$107.22
7D
2.7%
1Y
2.6%
Waters
Market Cap: US$36.4b
Provides analytical workflow solutions in Asia, the Americas, and Europe.
WAT
US$363.18
7D
-4.4%
1Y
5.0%
BioLife Solutions
Market Cap: US$1.3b
Develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.
BLFS
US$26.66
7D
-2.2%
1Y
12.3%
Sotera Health
Market Cap: US$4.7b
Provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally.
SHC
US$16.27
7D
6.5%
1Y
34.9%
Repligen
Market Cap: US$7.3b
A life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
RGEN
US$130.76
7D
7.4%
1Y
-0.9%